Hyalure: Italian Beauty Innovation Enters the Japanese Market
Introduction
Hyalure, an Italian company, recently made waves by officially entering the Japanese market, thanks to a collaboration with Doctors Pharmacy, a company dedicated to facilitating the personal import of overseas pharmaceuticals for physicians in Japan. This partnership aims to introduce cutting-edge beauty medical solutions to Japan, particularly focusing on their innovative dermal fillers. With this venture, both companies are determined to redefine standards in aesthetic healthcare, combining international innovation with local practices.
Background of the Partnership
Doctors Pharmacy, headquartered in Osaka, has a vision of empowering medical professionals across Japan by providing access to global medical solutions that adhere to the highest standards of safety and efficacy. Their commitment to enhancing the treatment environment in Japan reflects a broader mission - to create a society where individuals can experience richness in life through beauty and health.
On the flip side, Hyalure prides itself on its mission to foster a space where innovation meets timeless beauty. The company's products are crafted with advanced technology, setting new benchmarks in the global aesthetic market. Their unique approaches, including proprietary cross-linking technology and hybrid bio-link technology, allow for the development of high-performance dermal fillers.
Hyalure's Innovative Technology
1. Next-Generation Dermal Fillers: The company uses a unique cross-linking technique paired with high-purity raw materials to create next-generation dermal fillers. The fillers are cross-linked using a planetary mixer, resulting in a homogeneous mixture with excellent viscosity and minimal air incorporation, producing a dense hydrogel.
2. Safety Through Low BDDE Residuals: Safety standards are paramount in medical aesthetics. The use of butanediol diglycidyl ether (BDDE) as a cross-linking agent in hyaluronic acid is closely monitored, with Hyalure’s products boasting a remarkably low residual level of 0.1ppm or less. This not only surpasses safety norms but also ensures patient peace of mind when it comes to treatment.
3. Innovative CMC-Based Fillers: Hyalure's Erelle series uses carboxymethyl cellulose sodium (CMC), a highly pure absorbable polymer, differing significantly from traditional hyaluronic acid fillers. The materials are entirely animal-free and devoid of bacterial endotoxins and proteins, enhancing their biocompatibility. This results in fillers that cause less swelling post-injection and ensure a seamless experience for both physicians and patients alike.
Future Prospects
As both companies join forces, their joint efforts will bring Hyalure’s line of hyaluronic acid and CMC-based aesthetic products to Japanese healthcare. They are committed to encouraging a safer, more natural outcome in aesthetic procedures, thereby creating a new value proposition in the Japanese beauty medical market. The collaboration endeavors to contribute to an innovative landscape tailored for medical professionals and patients seeking top-tier aesthetic experiences.
Company Overview
- - Hyalure Aesthetics
Managing Director: Matteo O. Belamhawal
Business: Providing solutions in medical devices and dermal fillers
URL: hyalure.com
- - Doctors Pharmacy Co., Ltd.
Representative: President Hidetoshi Fujisawa
Business: Importing overseas pharmaceuticals and supporting regenerative medicine and clinic marketing
URL: drs-pharmacy.co.jp
Contact Information
For inquiries, please reach out to the Tokyo Office of Doctors Pharmacy:
Contact Person: Watanabe
Phone: 0120-929-635
Email: [email protected]
Topics Consumer Products & Retail）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.